Terms: = Pancreatic cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Clinical Outcome
24 results:
1. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
[TBL] [Abstract] [Full Text] [Related]
2. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract] [Full Text] [Related]
3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
4. Epigenetic upregulation of MNAT1 by SMYD2 is linked to PI3K/AKT activation and tumorigenesis of pancreatic adenocarcinoma.
Xu Z; Liu Y; Pan Z; Qin L
Histol Histopathol; 2024 Feb; 39(2):263-277. PubMed ID: 37232506
[TBL] [Abstract] [Full Text] [Related]
5. NSD3, a member of nuclear receptor-binding set domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract] [Full Text] [Related]
6. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
[TBL] [Abstract] [Full Text] [Related]
7. [An "a la carte" treatment for patients with pancreatic adenocarcinoma].
Iovanna J; Dusetti N
Medicina (B Aires); 2022; 82(4):571-573. PubMed ID: 35904914
[TBL] [Abstract] [Full Text] [Related]
8. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma.
Wen C; Deng X; Ren D; Song X; Chen H; Wang J; Jin J; Cheng D; Xu Z; Zhang J; Xie J; Qi W; Gu J; Peng C; Chen D; Chen S; Shen B; Zhan Q
Cancer Med; 2020 Oct; 9(20):7626-7636. PubMed ID: 32862515
[TBL] [Abstract] [Full Text] [Related]
9. Radiomics: A primer for the radiation oncologist.
Bibault JE; Xing L; Giraud P; El Ayachy R; Giraud N; Decazes P; Burgun A; Giraud P
Cancer Radiother; 2020 Aug; 24(5):403-410. PubMed ID: 32265157
[TBL] [Abstract] [Full Text] [Related]
10. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1.
Steins A; van Mackelenbergh MG; van der Zalm AP; Klaassen R; Serrels B; Goris SG; Kocher HM; Waasdorp C; de Jong JH; Tekin C; Besselink MG; Busch OR; van de Vijver MJ; Verheij J; Dijk F; van Tienhoven G; Wilmink JW; Medema JP; van Laarhoven HW; Bijlsma MF
EMBO Rep; 2020 May; 21(5):e48780. PubMed ID: 32173982
[TBL] [Abstract] [Full Text] [Related]
11. Glycolysis-Based Genes Associated with the clinical outcome of pancreatic Ductal Adenocarcinoma Identified by The cancer Genome Atlas Data Analysis.
Tian G; Li G; Liu P; Wang Z; Li N
DNA Cell Biol; 2020 Mar; 39(3):417-427. PubMed ID: 31968179
[TBL] [Abstract] [Full Text] [Related]
12. P4HA1/HIF1α feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.
Cao XP; Cao Y; Li WJ; Zhang HH; Zhu ZM
Biochem Biophys Res Commun; 2019 Aug; 516(3):606-612. PubMed ID: 31239153
[TBL] [Abstract] [Full Text] [Related]
13. E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments.
Lan W; Bian B; Xia Y; Dou S; Gayet O; Bigonnet M; Santofimia-Castaño P; Cong M; Peng L; Dusetti N; Iovanna J
Sci Rep; 2018 May; 8(1):8330. PubMed ID: 29844366
[TBL] [Abstract] [Full Text] [Related]
14. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
Iovanna J; Dusetti N
Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
[TBL] [Abstract] [Full Text] [Related]
15. Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome.
Luo L; McGarvey P; Madhavan S; Kumar R; Gusev Y; Upadhyay G
Oncotarget; 2016 Mar; 7(10):11165-93. PubMed ID: 26862846
[TBL] [Abstract] [Full Text] [Related]
16. Inhibition of CD47 Effectively Targets pancreatic cancer Stem Cells via Dual Mechanisms.
Cioffi M; Trabulo S; Hidalgo M; Costello E; Greenhalf W; Erkan M; Kleeff J; Sainz B; Heeschen C
Clin Cancer Res; 2015 May; 21(10):2325-37. PubMed ID: 25717063
[TBL] [Abstract] [Full Text] [Related]
17. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.
Robertson S; Hyder O; Dodson R; Nayar SK; Poling J; Beierl K; Eshleman JR; Lin MT; Pawlik TM; Anders RA
Hum Pathol; 2013 Dec; 44(12):2768-73. PubMed ID: 24139215
[TBL] [Abstract] [Full Text] [Related]
18. The clinical impact of uncertainties in the mean excitation energy of human tissues during proton therapy.
Besemer A; Paganetti H; Bednarz B
Phys Med Biol; 2013 Feb; 58(4):887-902. PubMed ID: 23337713
[TBL] [Abstract] [Full Text] [Related]
19. Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes.
Winter C; Kristiansen G; Kersting S; Roy J; Aust D; Knösel T; Rümmele P; Jahnke B; Hentrich V; Rückert F; Niedergethmann M; Weichert W; Bahra M; Schlitt HJ; Settmacher U; Friess H; Büchler M; Saeger HD; Schroeder M; Pilarsky C; Grützmann R
PLoS Comput Biol; 2012; 8(5):e1002511. PubMed ID: 22615549
[TBL] [Abstract] [Full Text] [Related]
20. Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer.
Dong X; Tang H; Hess KR; Abbruzzese JL; Li D
Cancer; 2011 Feb; 117(3):480-91. PubMed ID: 20845477
[TBL] [Abstract] [Full Text] [Related]
[Next]
